# NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/par-25-139-nci-clinical-and-translational-exploratory-developmental/  
Official notice: https://www.grants.gov/search-results-detail/356950

> National Institutes of Health offered grants of up to $275,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $200,000 in total. Applications closed on September 7, 2025.

| Field | Value |
|---|---|
| Opportunity number | PAR-25-139 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | September 7, 2025 |
| Award ceiling | $275,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | $200,000 |
| Cost sharing | not required |
| Assistance Listings | 93.393, 93.394, 93.395, 93.396, 93.399 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

## Questions people ask

### Is PAR-25-139 still open?

No. It closed on September 7, 2025.

### Who can apply for NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)?

Closed September 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $275,000 each. About $200,000 in total.

### Who has been funded under PAR-25-139?

NIH RePORTER lists 73 projects funded under PAR-25-139 in fiscal 2026, at 48 institutions. The most were at Albert Einstein College of Medicine, Washington University, University of TX MD Anderson Can Ctr.

### Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.